



In vitro Neuroprotection Screen for Alzheimer's Disease

SynAging uses proprietary amyloid- β oligomer (A β O) preparations to model Alzheimer's disease in tissue culture. Neuronal cultures are grown for 14 days and neurodegeneration is induced by 1 μ M A β O, resulting in ~50 % cell death within 24h:

Following A β O and compound treatment, determination of cell viability after 24h, is SynAging's standard approach for evaluating a test compound's neuroprotective efficacy.

Multiple other readouts are well established and regularly performed:



A β O preparations of the following established amyloid peptides are routinely evaluated in our screen:

A β_{1-42} , A β_{1-40} , A β_{11-40} , A β_{11-42} , pE(3)A β_{3-42} , pE(3)A β_{3-40} , A β_{4-40} , A β_{4-42}



Others can be evaluated upon request.

The following cultures are available for testing at SynAging:

- Hippocampal neurons (rat / mouse)
- Cortical neurons (rat / mouse)
- Striatal neurons (rat / mouse)
- Primary astrocytes (rat / mouse)
- Neuronal and glial cell lines (rat / mouse)

Clinical reference compound testing: neither Dimebon nor Donepezil were able to prevent A β O induced neurodegeneration in SynAging's model. However, the positive control, human anti-apoptotic peptide humanin (Yen, *et al.*, 2013, J Mol Endocrinol.; 50(1):R11-9) rescues the model successfully.

SynAging's model shows very high reproducibility of A β O induced neuronal cell death. Quality control performed over three months using five batches of A β O, resulted in 43.58 ± 0.60 % (mean \pm SEM) neuronal cell death.



SynAging SAS: Your partner in naturally induced phenotypic models, accelerating drug discovery for proteopathic CNS diseases